Atlas Trials

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Clinical trial NCT04866381 · UNKNOWN

Trial details

NCT number
NCT04866381
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell CarcinomaProgression to PD-1 Antibody
Start date
2021-04-01
Primary completion
2023-04-01
Enrollment
87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.